首页 | 本学科首页   官方微博 | 高级检索  
     


Real-world dosing of omalizumab for chronic spontaneous urticaria
Affiliation:1. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts;2. NYC Health + Hospitals, Jacobi Medical Center, New York, New York;3. Lenox Hill Hospital, Northwell Health, New York, New York;4. Vanderbilt University Medical Center, Nashville, Tennessee;5. Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York;1. Photodermatosis Clinic, Department of Dermatology, Rabin Medical Center, Petah-Tikva, Israel;2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;3. Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel;4. Allergy and Clinical Immunology Unit, Department of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel;5. Allergy and Clinical Immunology Unit, Meir Medical Center, Kfar-Saba, Israel;1. Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China;2. Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China;3. National Clinical Research Center for Skin and Immune Diseases, Beijing, China;4. Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy Charité-Universitatsmedizin Berlin, Berlin, Germany;6. Peking University School of Nursing, Beijing, China;1. Division of Allergy & Immunology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas;2. Department of Dermatology, Koç University School of Medicine, Istanbul, Turkey;3. Department of Dermatology, University Allergy Center, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany;4. Department for Children and Adolescents, University Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, Frankfurt, Germany
Abstract:
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号